Hillsdale Investment Management Inc.
Position in SUPN — Supernus Pharmaceuticals, Inc.
CIK 1368465
Toronto, A6
Position in SUPN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$4,822,156
+$4,816,261 QoQ
Shares Held
103,680
+57500.0% QoQ
Ownership
0.178%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#63
of 331 holders
Holding Since
Mar 2025
2 quarters on record
Voting authority
Sole 80%
Shared 0%
None 20%
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Hillsdale Investment Management Inc. holds $42,212,910 across 9 Drug Manufacturers - Specialty & Generic names. SUPN ranks #5 (11.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMRX |
Amneal Pharmaceuticals, Inc.
|
649,179 | $11,237,288 | |
| 2 | PCRX |
Pacira BioSciences, Inc.
|
362,700 | $9,201,699 | |
| 3 | COLL |
Collegium Pharmaceutical, Inc
|
191,600 | $6,935,920 | |
| 4 | IRWD |
Ironwood Pharmaceuticals Inc
|
1,250,428 | $5,264,301 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
103,680 | $4,822,156 | |
| 6 | ANIK |
Anika Therapeutics, Inc.
|
138,821 | $2,030,951 | |
| 7 | VTRS |
Viatris Inc
|
117,650 | $1,868,282 | |
| 8 | LQDA |
Liquidia Corp
|
6,070 | $483,961 |
All Filings in SUPN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,822,156 | 103,680 | Shares | Sole | 2026-08-12 | |
| 2025-03-31 | $5,895 | 180 | Shares | Sole | 2025-05-09 | |
| No filing history on record for this holder in this stock. | ||||||